Extracorporeal liver support and liver transplantation for acute‐on‐chronic liver failure
Liver International · 2025
DOI: 10.1111/liv.15647 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, 2025. Verfasst von Maria Pilar Ballester und 2 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Disease Department, Hospital Clínico Universitario de Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure, Liver Transplantation, Extracorporeal Circulation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Acute‐on‐chronic liver failure (ACLF) is defined by acute decompensation, organ failure and a high risk of short‐term mortality. This condition is characterized by an overwhelming systemic inflammatory response. Despite treating the precipitating event, intensive monitoring and organ support, clinical deterioration can occur with very poor outcomes. During the last decades, several extracorporeal liver support systems have been developed to try to reduce ongoing liver injury and provide an improved environment for the liver to regenerate or as a bridging therapy until liver transplantation. Several clinical trials have been performed to evaluate the clinical efficacy of extracorporeal liver support systems, but no clear impact on survival has been proven. DIALIVE is a novel extracorporeal liver support device that has been built to specifically address the pathophysiological derangements responsible for the development of ACLF by replacing dysfunctional albumin and removing pathogen and damage‐associated molecular patterns (PAMPs and DAMPs). In phase II clinical trial, DIALIVE appears to be safe, and it seems to be associated with a faster time to the resolution of ACLF compared with standard medical treatment. Even in patients with severe ACLF, liver transplantation saves lives and there is clear evidence of transplant benefit. Careful selection of patients is required to attain good results from liver transplantation, but many questions remain unanswered. In this review, we describe the current perspectives on the use of extracorporeal liver support and liver transplantation for ACLF patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Digestive Disease Department, Hospital Clínico Universitario de Valencia, Valencia, Spain.
- INCLIVA Biomedical Research Institute, Hospital Clínico Universitario de Valencia, Valencia, Spain.
- Liver Failure Group, Institute for Liver & Digestive Health, University College London, London, UK.
- Endemic Hepatology and Gastroenterology Department, Mansoura University, Mansoura, Egypt.
- European Foundation for the Study of Chronic Liver Failure (EF Clif), Barcelona, Spain.
ORCID-Profile: Maria Pilar Ballester
Zitieren
APA
Ballester, M. P., Elshabrawi, A., & Jalan, R. (2025). Extracorporeal liver support and liver transplantation for acute‐on‐chronic liver failure. Liver International. https://doi.org/10.1111/liv.15647
Vancouver
Ballester MP, Elshabrawi A, Jalan R. Extracorporeal liver support and liver transplantation for acute‐on‐chronic liver failure. Liver International. 2025. doi:10.1111/liv.15647
BibTeX
@article{Ballester2025,
author = {Ballester, Maria Pilar and Elshabrawi, Ahmed and Jalan, Rajiv},
title = {Extracorporeal liver support and liver transplantation for acute‐on‐chronic liver failure},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.15647}
}
EUVIMED